Hürrem Gül Öngen
Hürrem Gül Öngen has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Abdullah Aldalaan
Department of Pulmonary Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
1 shared publicationAlexander Chernyavsky
E. Meshalkin National Medical Research Center of the Ministry of Health of the Russian Federation, Moscow, Russian Federation
1 shared publicationAnuar Omarov
Institute of Cardiology in Almaty, Almaty, Kazakhstan
1 shared publicationBahri Akdeniz
Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey
1 shared publication- Bilgehan Karadag
Department of Cardiology, İstanbul University-Cerrahpaşa Faculty of Medicine, İstanbul, Türkiye
1 shared publication Bülent Mutlu
Faculty of Medicine, Marmara University, Istanbul, TURKEY
1 shared publication
Latest Publications
- Open Access
- 30 July 2025
- Published by AVES YAYINCILIK A.Ş. in Cerrahpasa Medical Journal
- Vol. 49 (1) , 1-9
Factors Related to 6-Minute Walk Distance in Pulmonary Arterial Hypertension
Objective: The 6-minute walk test is the most commonly used tool for evaluating prognosis in patients withpulmonary arterial hypertension (PAH). This study aims to identify the parameters associated with 6-minutewalk distance (6MWD) and its changes over time.Methods: Sixty-three patients diagnosed with PAH or chronic thromboembolic pulmonary hypertensionbetween January 2005 and January 2013 were included in the study. Demographic, clinical, echocardiographic, hemodynamic data, and initial and follow-up 6MWD were recorded. The 6MWD cut-off wasdetermined based on previous studies. Patients were then categorized into groups based on their initial6MWD: ≥ 332 m or < 332 m.Results: Patients were followed up for 31.56 ± 15.07 months. In those with a 6MWD < 332m, diffusingcapacity of the lungs for carbon monoxide (DLCO) (P = .040), estimated glomerular filtration rate (P = .018),and partial arterial oxygen pressure (PaO2) (P = .024) were significantly lower, whereas age (P = .016), rightatrial pressure (P = .034), the frequency of pericardial effusion (P = .004), and mortality (P = .020) weresignificantly higher. Low DLCO was identified as an independent predictor of walking less than 332 meters(P = .048). In the subgroup analysis, among idiopathic PAH (IPAH) patients, DLCO (P = .024) was lower inthose with 6MWD < 332 m. In patients with scleroderma-associated PAH (SSc-PAH), systolic pulmonaryartery pressure (sPAP) (P = .018), and mean PAP (p = 0.034) were higher in patients with 6MWD < 332 m.When the change in 6MWD (Δ6MWD) was evaluated based on the difference between the initial 6MWDand at the end of the follow-up period, DLCO was lower in the group with a decreased 6MWD (P < .001).Conclusion: The study identified higher DLCO as an independent predictor of 6MWD ≥ 332 m and itsimprovement over time. In IPAH, 6MWD is more closely associated with DLCO and PaO2, whereas in SScPAH, PAPs play a more significant role.Cite this article as: Yurtseven E, Özcan S, Karadağ B, Öngen HG, Öngen Z. Factors related to 6-minute walk distance in pulmonaryarterial hypertension. Cerrahpaşa Med J 2025, 49, 0015, doi: 10.5152/cjm.2025.25015.
- 30 July 2025
- Published by AVES YAYINCILIK A.Ş. in Cerrahpasa Medical Journal
- Vol. 49 (1) , 1-9
Open AccessFactors Related to 6-Minute Walk Distance in Pulmonary Arterial Hypertension
Objective: The 6-minute walk test is the most commonly used tool for evaluating prognosis in patients withpulmonary arterial hypertension (PAH). This study aims to identify the parameters associated with 6-minutewalk distance (6MWD) and its changes over time.Methods: Sixty-three patients diagnosed with PAH or chronic thromboembolic pulmonary hypertensionbetween January 2005 and January 2013 were included in the study. Demographic, clinical, echocardiographic, hemodynamic data, and initial and follow-up 6MWD were recorded. The 6MWD cut-off wasdetermined based on previous studies. Patients were then categorized into groups based on their initial6MWD: ≥ 332 m or < 332 m.Results: Patients were followed up for 31.56 ± 15.07 months. In those with a 6MWD < 332m, diffusingcapacity of the lungs for carbon monoxide (DLCO) (P = .040), estimated glomerular filtration rate (P = .018),and partial arterial oxygen pressure (PaO2) (P = .024) were significantly lower, whereas age (P = .016), rightatrial pressure (P = .034), the frequency of pericardial effusion (P = .004), and mortality (P = .020) weresignificantly higher. Low DLCO was identified as an independent predictor of walking less than 332 meters(P = .048). In the subgroup analysis, among idiopathic PAH (IPAH) patients, DLCO (P = .024) was lower inthose with 6MWD < 332 m. In patients with scleroderma-associated PAH (SSc-PAH), systolic pulmonaryartery pressure (sPAP) (P = .018), and mean PAP (p = 0.034) were higher in patients with 6MWD < 332 m.When the change in 6MWD (Δ6MWD) was evaluated based on the difference between the initial 6MWDand at the end of the follow-up period, DLCO was lower in the group with a decreased 6MWD (P < .001).Conclusion: The study identified higher DLCO as an independent predictor of 6MWD ≥ 332 m and itsimprovement over time. In IPAH, 6MWD is more closely associated with DLCO and PaO2, whereas in SScPAH, PAPs play a more significant role.Cite this article as: Yurtseven E, Özcan S, Karadağ B, Öngen HG, Öngen Z. Factors related to 6-minute walk distance in pulmonaryarterial hypertension. Cerrahpaşa Med J 2025, 49, 0015, doi: 10.5152/cjm.2025.25015.
- Open Access
- 21 February 2024
- Published by Springer Nature in Drugs - Real World Outcomes
- Vol. 11 (1) , 149-165
Diagnosis and Treatment Patterns of Chronic Thromboembolic Pulmonary Hypertension in Russia, Kazakhstan, Turkey, Lebanon, and Saudi Arabia: A Registry Study
Background Patients with chronic thromboembolic pulmonary hypertension (CTEPH) in countries with limited resources have, to date, been poorly represented in registries. Objective This work assesses the epidemiology, diagnosis, hemodynamic and functional parameters, and treatment of CTEPH in Russia, Kazakhstan, Turkey, Lebanon, and Saudi Arabia. Methods A prospective, cohort, phase IV, observational registry with 3-year follow-up (n = 212) in patients aged ≥ 18 years diagnosed with CTEPH was created. Clinical, hemodynamic, and functional parameters were obtained at an initial visit, follow-up visits, and a final visit at the end of 3 years’ observation or end of follow-up. Data were recorded on electronic case report forms. Parameters evaluated included 6-minute walking distance (6MWD), use of pulmonary endarterectomy (PEA), balloon pulmonary angioplasty (BPA), pulmonary hypertension (PH)-targeted therapy, and survival. All statistical analyses were exploratory and descriptive, and were performed in the overall population. Results The most common symptoms were typical of those expected for CTEPH. Almost 90% of patients underwent right heart catheterization at diagnosis or initial study visit. In total, 66 patients (31%) underwent PEA before the initial visit; 95 patients (45%) were considered operable, 115 (54%) were inoperable, and two (1%) had no operability data. Only 26 patients (12%) had been assessed for BPA at their initial visit. PH-targeted therapy was documented at diagnosis for 77 patients (36%), most commonly a phosphodiesterase type 5 inhibitor (23%). Use of PH-targeted therapy increased to 142 patients (67%) at the initial visit, remaining similar after 3 years. Use of riociguat increased from 6% of patients at diagnosis to 38% at 3 years. Between baseline and end of observation, results for patients with paired data showed an increase in 6MWD. Survival at the end of observation was 88%. Conclusions These data highlight the current diagnosis and management of CTEPH in the participating countries. They show that early CTEPH diagnosis remains challenging, and use of off-label PH-targeted therapy is common. ClinicalTrials.gov: NCT02637050; registered December 2015. Graphical Abstract
- 21 February 2024
- Published by Springer Nature in Drugs - Real World Outcomes
- Vol. 11 (1) , 149-165
Open AccessDiagnosis and Treatment Patterns of Chronic Thromboembolic Pulmonary Hypertension in Russia, Kazakhstan, Turkey, Lebanon, and Saudi Arabia: A Registry Study
Background Patients with chronic thromboembolic pulmonary hypertension (CTEPH) in countries with limited resources have, to date, been poorly represented in registries. Objective This work assesses the epidemiology, diagnosis, hemodynamic and functional parameters, and treatment of CTEPH in Russia, Kazakhstan, Turkey, Lebanon, and Saudi Arabia. Methods A prospective, cohort, phase IV, observational registry with 3-year follow-up (n = 212) in patients aged ≥ 18 years diagnosed with CTEPH was created. Clinical, hemodynamic, and functional parameters were obtained at an initial visit, follow-up visits, and a final visit at the end of 3 years’ observation or end of follow-up. Data were recorded on electronic case report forms. Parameters evaluated included 6-minute walking distance (6MWD), use of pulmonary endarterectomy (PEA), balloon pulmonary angioplasty (BPA), pulmonary hypertension (PH)-targeted therapy, and survival. All statistical analyses were exploratory and descriptive, and were performed in the overall population. Results The most common symptoms were typical of those expected for CTEPH. Almost 90% of patients underwent right heart catheterization at diagnosis or initial study visit. In total, 66 patients (31%) underwent PEA before the initial visit; 95 patients (45%) were considered operable, 115 (54%) were inoperable, and two (1%) had no operability data. Only 26 patients (12%) had been assessed for BPA at their initial visit. PH-targeted therapy was documented at diagnosis for 77 patients (36%), most commonly a phosphodiesterase type 5 inhibitor (23%). Use of PH-targeted therapy increased to 142 patients (67%) at the initial visit, remaining similar after 3 years. Use of riociguat increased from 6% of patients at diagnosis to 38% at 3 years. Between baseline and end of observation, results for patients with paired data showed an increase in 6MWD. Survival at the end of observation was 88%. Conclusions These data highlight the current diagnosis and management of CTEPH in the participating countries. They show that early CTEPH diagnosis remains challenging, and use of off-label PH-targeted therapy is common. ClinicalTrials.gov: NCT02637050; registered December 2015. Graphical Abstract